Global Drug Discovery Market to Exceed $174.92 Billion by 2035

Key Takeaways

• SNS Insider estimate: $71.95B market size in 2025 and $174.92B by 2035 at 9.29% CAGR (2026-2035).
• U.S. drug discovery spend in the same release is projected from about $24.53B in 2025 to $62.14B by 2035 (9.74% CAGR).
• Segment lenses cited include target identification, hit-to-lead, HTS, bioinformatics, small molecules, biologics, and CRO end users.
• FDA development-process materials remain the compliance frame for turning discovery spend into approvable packages.

What forecast does the drug discovery market release cite?

According to the GlobeNewswire SNS Insider release, the drug discovery market was valued at $71.95 billion in 2025 and is projected to surpass $174.92 billion by 2035.

The implied growth rate is a 9.29% compound annual growth rate over 2026-2035.

How large is the U.S. slice of drug discovery spend?

The same release estimates U.S. drug discovery market value at about $24.53 billion in 2025 and about $62.14 billion by 2035, a 9.74% CAGR.

It attributes U.S. leadership to academic biology, large-pharma R&D infrastructure, and CRO capacity for advanced discovery science.

Which process and technology segments are highlighted?

• Process: target identification and validation, hit-to-lead, candidate validation
• Technology: high-throughput screening, bioinformatics, molecular modeling, genomics
• Drug type: small molecules, biologics, and other modalities
• End users: pharma/biotech companies, CROs, academic institutes

Buyers should map vendor claims to these buckets before treating a platform as full-pipeline coverage.

How should APAC operators use the forecast?

APAC CDMOs and discovery CROs can cite global CAGR only alongside local regulatory and talent constraints.

China pathway timing still depends on NMPA practice; pair market sizing with primary regulator reading rather than vendor decks alone. For U.S. translation risk, use the FDA development and approval process overview.

What clinical registry signal complements market sizing?

Active interventional volume on ClinicalTrials.gov remains a reality check on whether discovery tools are converting into human studies.

A rising discovery TAM with flat early-phase starts usually means tooling spend is outrunning pipeline productivity.

What remains unproven in the $174.92B outlook?

SNS Insider figures are commercial market-research estimates distributed by GlobeNewswire; they are not audited national accounts or FDA statistics.

Modality-level share, company-level revenue attribution, and regional CAGR splits beyond the cited release should not be invented.

How should buyers read the $174.92 billion forecast?

Treat the SNS Insider CAGR as a planning range and triangulate with internal pipeline counts and CRO backlog data.

Split budgets across target ID, hit-to-lead, and candidate validation rather than funding a single black-box discovery platform.

Compare U.S. 9.74% CAGR assumptions with APAC hiring and regulator timelines before relocating discovery seats.

Ask vendors for 2022-2024 historicals that sit behind the 2025 $71.95 billion base year cited in the release.

Related NovaPharma coverage

• Drug discovery technology market to 2035
• NMPA drug approvals 2025
• Clinical trials outsourcing outlook

Frequently Asked Questions

Primary Sources

1. GlobeNewswire: SNS Insider drug discovery forecast
2. FDA: drug development and approval process
3. ClinicalTrials.gov registry home